US Edition
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
- On August 5, 2024, Actinium Pharmaceuticals announced that the FDA required an additional clinical trial before accepting the BLA filing for its lead product lomab-B in the U.S.
- This regulatory update followed FDA feedback that the Sierra trial data did not meet guidelines, prompting Actinium to conduct more studies to support the BLA.
- Following the announcement, Actinium's share price dropped from $6.17 on August 2 to $2.48 by August 5, 2024, coinciding with allegations that the company misled investors about its data reliability.
- A federal securities class action has been initiated against defendants for allegedly making false or misleading statements during the period spanning late 2022 through mid-2024. Investors who acquired Actinium Pharmaceuticals, Inc. Securities within this timeframe may be eligible to seek damages without any upfront costs. The deadline to apply for lead plaintiff status is May 26, 2025.
- This lawsuit and upcoming deadline present a potential opportunity for investors who acquired Actinium Pharmaceuticals, Inc. Securities within the specified Class Period to seek compensation related to disputes over the Iomab-B BLA data.
Insights by Ground AI
Does this summary seem wrong?
42 Articles
42 Articles
All
Left
3
Center
13
Right
7
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit - Actinium Pharma (AMEX:ATNM)
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching May 27, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM) securities during the period from October 31, 2022, through August 2, 2024 ("the Class Period"). [LEARN MORE ABOUT THE CLASS A…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources42
Leaning Left3Leaning Right7Center13Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
13%
C 57%
R 30%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
